Jensen Märit, Al-Shahi Salman Rustam, Ng G Andre, van der Worp H Bart, Loh Peter, Campbell Bruce C V, Kalman Jonathan M, Hill Michael D, Sposato Luciano A, Andrade Jason G, Metzner Andreas, Kirchhof Paulus, Thomalla Götz
Department of Neurology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.
German Centre for Cardiovascular Research (DZHK e.V.), Partner Site Hamburg/Kiel/Lübeck, Hamburg, Germany.
Neurol Res Pract. 2023 Jul 6;5(1):29. doi: 10.1186/s42466-023-00255-7.
Patients with ischemic stroke and atrial fibrillation (AF) are at particularly high risk for recurrent stroke and cardiovascular events. Early rhythm control has been shown to be superior to usual care for the prevention of stroke and cardiovascular events for people with early AF. There are no data on the willingness to use rhythm control for patients with AF and acute ischemic stroke in clinical practice.
An online survey was carried out among stroke physicians to assess current practice and attitudes toward rhythm control in patients with AF and acute ischemic stroke between December 22nd 2021 and March 24th 2022.
The survey was completed by 277 physicians including 237 from 15 known countries and 40 from unspecified countries. 79% (210/266) reported that they do not regularly apply treatment for rhythm control by ablation or antiarrhythmic drugs at all or only in small numbers (≤ 10%) of patients with AF and acute ischemic stroke. In those patients treated with rhythm-control therapy, antiarrhythmic drugs were used by the majority of respondents (89%), while only a minority reported using AF ablation (11%). 88% of respondents (221/250) stated that they would be willing to randomize patients with AF after acute ischemic stroke to either early rhythm control or usual care in a clinical trial.
Despite its potential benefit, few patients with AF and acute ischemic stroke appear to be treated with rhythm control, which may result from uncertainty regarding potential complications of antiarrhythmic therapy in patients with acute stroke. Together with recent data on the effectiveness of early rhythm control in patients with a history of stroke, these results call for a randomized clinical trial to assess the efficacy of early rhythm control in patients with acute ischemic stroke and AF.
缺血性中风和心房颤动(AF)患者发生复发性中风和心血管事件的风险特别高。对于早期房颤患者,早期节律控制已被证明在预防中风和心血管事件方面优于常规治疗。在临床实践中,尚无关于房颤合并急性缺血性中风患者使用节律控制的意愿的数据。
在2021年12月22日至2022年3月24日期间,对中风科医生进行了一项在线调查,以评估他们对房颤合并急性缺血性中风患者当前的治疗实践和对节律控制的态度。
277名医生完成了调查,其中237名来自15个已知国家,40名来自未指明的国家。79%(210/266)的医生报告称,他们根本不经常或仅对少数(≤10%)房颤合并急性缺血性中风患者采用消融或抗心律失常药物进行节律控制治疗。在接受节律控制治疗的患者中,大多数受访者(89%)使用了抗心律失常药物,而只有少数人报告使用房颤消融术(11%)。88%的受访者(221/250)表示,他们愿意在一项临床试验中将急性缺血性中风后房颤患者随机分为早期节律控制组或常规治疗组。
尽管节律控制有潜在益处,但似乎很少有房颤合并急性缺血性中风患者接受节律控制治疗,这可能是由于急性中风患者抗心律失常治疗潜在并发症的不确定性所致。结合近期关于中风病史患者早期节律控制有效性的数据,这些结果呼吁进行一项随机临床试验,以评估早期节律控制对急性缺血性中风合并房颤患者的疗效。